Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Raab

Showing results (311-320 of 427) with videos related to

Pageof 43
Sort By:
Cell Reports|August 24, 2017
Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in CancerMarco R Cosenza, Anna Cazzola, Annik Rossberg, et al.
Clinical Biochemistry|July 4, 2012
Effectiveness of barcoding for reducing patient specimen and laboratory testing identification errors: a Laboratory Medicine Best Practices systematic review and meta-analysisSusan R Snyder, Alessandra M Favoretto, James H Derzon, et al.
Cells|May 24, 2024
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple MyelomaAnna Luise Grab, Peter S Kim, Lukas John, et al.
Leukemia|March 23, 2007
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yieldI Breitkreutz, H M Lokhorst, M S Raab, et al.
Archives of Pathology & Laboratory Medicine|May 13, 2015
Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center and the Association of Directors of Anatomic and Surgical PathologyRaouf E Nakhleh, Vania Nosé, Carol Colasacco, et al.
Oncoimmunology|October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myelomaMohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
The Lancet. Haematology|March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trialMarc S Raab, Monika Engelhardt, Antje Blank, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2022
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 TrialMeletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Blood Advances|August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell levelCarolina Schinke, Alexandra M Poos, Michael Bauer, et al.
The Lancet. Haematology|December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyPaul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
Pageof 43

Showing results (311-320 of 427) with videos related to

Sort By:
Pageof 43
Cell Reports|August 24, 2017
Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in CancerMarco R Cosenza, Anna Cazzola, Annik Rossberg, et al.
Clinical Biochemistry|July 4, 2012
Effectiveness of barcoding for reducing patient specimen and laboratory testing identification errors: a Laboratory Medicine Best Practices systematic review and meta-analysisSusan R Snyder, Alessandra M Favoretto, James H Derzon, et al.
Cells|May 24, 2024
Pre-Clinical Assessment of SAR442257, a CD38/CD3xCD28 Trispecific T Cell Engager in Treatment of Relapsed/Refractory Multiple MyelomaAnna Luise Grab, Peter S Kim, Lukas John, et al.
Leukemia|March 23, 2007
Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yieldI Breitkreutz, H M Lokhorst, M S Raab, et al.
Archives of Pathology & Laboratory Medicine|May 13, 2015
Interpretive Diagnostic Error Reduction in Surgical Pathology and Cytology: Guideline From the College of American Pathologists Pathology and Laboratory Quality Center and the Association of Directors of Anatomic and Surgical PathologyRaouf E Nakhleh, Vania Nosé, Carol Colasacco, et al.
Oncoimmunology|October 6, 2018
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myelomaMohamed H S Awwad, Katharina Kriegsmann, Julian Plaumann, et al.
The Lancet. Haematology|March 15, 2020
MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trialMarc S Raab, Monika Engelhardt, Antje Blank, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 12, 2022
Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 TrialMeletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, et al.
Blood Advances|August 17, 2022
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell levelCarolina Schinke, Alexandra M Poos, Michael Bauer, et al.
The Lancet. Haematology|December 22, 2015
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation studyPaul G Richardson, Sundar Jagannath, Philippe Moreau, et al.
Pageof 43